Foghorn Therapeutics Inc. Stock Price, News & Analysis

Cellarity has appointed Ted Myles as its new Chief Executive Officer and CEO-Partner at Flagship Pioneering. Myles brings extensive biopharma leadership experience, previously serving as CFO and COO of Scholar Rock where he raised over $1 billion and led the company through a successful Phase 3 study. His prior roles include executive positions at AMAG Pharmaceuticals, Ocata Therapeutics, and PrimeraDx.

The appointment comes as Cellarity prepares for its first clinical study in 2025. The company leverages an AI/ML-enabled platform for drug discovery, focusing on understanding dysregulated pathways in diseased human cells. Their lead program, CLY-124, is a potential first-in-class small molecule for sickle cell disease treatment, targeting fetal hemoglobin induction through a novel mechanism, with clinical development expected to begin in mid-2025.

Foghorn Therapeutics (NASDAQ: FHTX), a clinical-stage biotech company focused on developing medicines that correct abnormal gene expression, announced its participation in the upcoming Citizens Life Sciences Conference in New York on May 7-8, 2025. CEO Adrian Gottschalk will present in a fireside chat on May 7 at 9:30 a.m. EST and participate in one-on-one meetings throughout the day. The company's Gene Traffic Control® platform primarily targets oncology applications and aims to develop treatments for a broad spectrum of diseases.

Foghorn Therapeutics (FHTX) has appointed two new members to its Board of Directors: Neil Gallagher, M.D., Ph.D., and Stuart Duty. The clinical-stage biotechnology company, which focuses on developing medicines that correct abnormal gene expression, will benefit from their extensive biotechnology industry experience. Both new directors expressed enthusiasm about Foghorn's potential in developing selective therapies for various cancers and its capabilities in selective protein degradation.

Flagship Pioneering and Quotient Therapeutics have appointed Rahul Kakkar, M.D. as CEO-Partner and Chief Executive Officer. Dr. Kakkar brings nearly 20 years of experience in biotech entrepreneurship and medicine, previously serving as CEO of Tome Biosciences and Pandion Therapeutics, which was acquired by Merck for $1.85 billion.

Jake Rubens, Quotient's co-founder and former CEO, will transition to a board director role after successfully establishing the company's first industrial platform for discovering drug targets through somatic genomics and securing a collaboration with Pfizer in cardiovascular and renal diseases.

Dr. Kakkar, who continues to practice at Brigham and Women's Hospital and lecture at Harvard Medical School, will lead Quotient's efforts in advancing its pipeline and platform technology. The company's focus on somatic genomics aims to discover novel drug targets and create first-in-class medicines for various diseases.

Foghorn Therapeutics presented new preclinical data at the 2025 AACR Annual Meeting, highlighting progress across multiple cancer treatment programs. The company's lead candidate, FHD-909, a selective SMARCA2 inhibitor, is advancing in Phase 1 trials targeting SMARCA4-mutated cancers, particularly non-small cell lung cancer (NSCLC).

Key developments include:

• FHD-909 showed enhanced anti-tumor activity when combined with pembrolizumab and KRAS inhibitors
• The Selective CBP degrader program demonstrated promising results in ER+ breast cancer models
• New data on the Selective EP300 degrader program for treating blood cancers
• Progress on the ARID1B degrader program, targeting up to 5% of all solid tumors

The company will host a virtual investor event on April 29, 2025, to review these pipeline updates. FHD-909's Phase 1 trial continues enrollment and dose escalation, with NSCLC as the primary target population, where SMARCA4 mutations occur in up to 10% of cases and often coincide with KRAS mutations.

Etiome, unveiled by Flagship Pioneering with a $50 million initial commitment, introduces its Temporal Biodynamics™ AI-powered platform for preemptive healthcare. The platform represents the first end-to-end solution to detect and preempt disease progression before it becomes critical.

The technology characterizes disease progression over time by combining multimodal population-level data and single cell omics with artificial intelligence. It identifies Biostage Markers - stage-specific biomarkers indicating patient disease progression - and develops targeted Biostaged Medicines.

Initially focusing on metabolic, neurodegenerative, pre-cancerous, and autoimmune diseases, Etiome aims to reduce morbidity, lower healthcare costs, and extend healthy lifespans. The company emerges after four years of platform development under Flagship Pioneering's Preemptive Health and Medicine Initiative.

Foghorn Therapeutics (NASDAQ: FHTX) has announced a virtual investor event scheduled for April 29, 2025, at 8:00 a.m. ET to discuss key pipeline updates coinciding with the 2025 AACR Annual Meeting.

The company will present new preclinical combination data for FHD-909 (LY4050784), their potential first-in-class selective SMARCA2 inhibitor, targeting primarily non-small cell lung cancer (NSCLC). Additionally, Foghorn will share updates on their:

• Selective CBP degrader program's preclinical data in combination with chemotherapy and targeted agents
• Selective EP300 degrader program in hematological malignancies
• Selective ARID1B degrader program overview

The virtual event will review presentations from the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025. The webcast will be available on Foghorn's website with replay access post-event.

Flagship Pioneering has announced a new collaboration between its drug discovery unit Pioneering Medicines and Pfizer to discover potential novel inhibitors for autoimmune disease treatment. The partnership will utilize Logica, a platform developed by Valo Health and Charles River that combines AI-powered technology with drug discovery expertise to translate biological insights into optimized small molecules.

This marks the sixth agreement under the strategic partnership between Flagship Pioneering and Pfizer, following previous collaborations with ProFound Therapeutics, Quotient Therapeutics, Montai Therapeutics, and Ampersand Biomedicines. The initiative aims to address the unmet needs in autoimmune disease management by developing more effective, safer, and personalized treatment options.

Foghorn Therapeutics (FHTX) announced new preclinical data presentations for its cancer treatment programs at the 2025 AACR Meeting. The company's lead candidate, FHD-909, a first-in-class selective SMARCA2 inhibitor, is currently advancing in Phase 1 trials for SMARCA4 mutated cancers, primarily targeting non-small cell lung cancer (NSCLC).

The presentations will showcase new preclinical combination data for FHD-909 with chemotherapy, pembrolizumab, and KRAS inhibitors. Additionally, the company will present data on their Selective CBP degrader and Selective EP300 degrader programs, which have demonstrated selective and robust anti-tumor activities.

The data will be presented through an oral presentation and multiple poster sessions at the AACR Annual Meeting in Chicago from April 25-30, 2025. The company reports that enrollment and dose escalation for the FHD-909 Phase 1 trial are progressing as planned.